Skip to main content

Mast Cell Disorder

0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Imagine Pharma
Imagine PharmaPA - Pittsburgh
1 program
Epidemiological Data on Mast Cell Pathologies in FranceN/A1 trial
Active Trials
NCT06186856Recruiting13,000Est. Dec 2038

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
2029
2030
2031
Imagine PharmaEpidemiological Data on Mast Cell Pathologies in France

Clinical Trials (1)

Total enrollment: 13,000 patients across 1 trials

NCT06186856Imagine PharmaEpidemiological Data on Mast Cell Pathologies in France

Epidemiological Data on Mast Cell Pathologies in France

Start: Nov 2024Est. completion: Dec 203813,000 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 13,000 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.